Zydus launches biosimilar for treatment of multiple cancers
- IBEF
- January 23, 2026
Zydus Lifesciences has launched Tishtha, the first biosimilar of Nivolumab in the world, in India. This is a major achievement for India in making world-class cancer treatments more accessible. Nivolumab is a popular immuno-oncology drug used for treating various types of cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, and Hodgkin lymphoma. The launch of Tishtha further cements the capabilities of India in handling complex biologic molecules and immunotherapy, making the country an important player in making cancer treatment more accessible and innovative at an affordable cost.
Zydus also said that Tishtha has been priced at almost one-fourth the cost of the reference drug, which will improve the affordability of the drug for patients. The 100 mg vial of the drug has been priced at Rs. 28,950 (US$ 322), and the 40 mg vial has been priced at Rs. 13,950 (US$ 155). The launch of this biosimilar is expected to make immuno-oncology therapy more accessible to patients in the Indian market. The launch of this biosimilar is also expected to ease the financial burden of cancer treatment for patients. The launch of this biosimilar also shows that the biologics manufacturing ecosystem in India is developing, which will further strengthen India’s position in the global biopharmaceutical value chain.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
